Roth Capital Partners Facilitates CapsoVision's $27.5 Million IPO

Roth Capital Partners, a leading investment bank, has successfully acted as joint book-running manager for CapsoVision, Inc.'s initial public offering (IPO), which raised approximately $27.5 million. CapsoVision, a commercial-stage medical technology company specializing in AI-powered capsule endoscopy solutions, offered 5,500,000 shares of common stock at $5.00 per share. The shares commenced trading on the Nasdaq Capital Market under the ticker symbol 'CV' on July 2, 2025. Additionally, the underwriters were granted a 30-day option to purchase up to an additional 825,000 shares at the IPO price, potentially increasing the total proceeds.

This IPO represents a significant achievement for CapsoVision, enabling the company to further its mission of revolutionizing gastrointestinal diagnostics through innovative technology. The involvement of Roth Capital Partners underscores the firm's expertise in facilitating capital raising for growth-oriented companies. For more details on the offering, visit https://ibn.fm/D3xFn.

The successful IPO of CapsoVision highlights the growing investor interest in medical technology companies that leverage artificial intelligence to improve patient outcomes. This development not only provides CapsoVision with the capital needed to accelerate its growth but also sets a precedent for similar companies in the healthcare sector seeking public investment. The role of Roth Capital Partners in this process exemplifies the critical function investment banks play in bridging innovative companies with the capital markets, fostering advancements in healthcare technology.